Brokerages Set Kymera Therapeutics, Inc. (NASDAQ:KYMR) Target Price at $118.90

Shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR) have earned a consensus rating of “Moderate Buy” from the twenty-two brokerages that are covering the firm, MarketBeat Ratings reports. One research analyst has rated the stock with a sell recommendation, twenty have given a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12 month target price among brokerages that have covered the stock in the last year is $118.90.

KYMR has been the topic of a number of research reports. Wall Street Zen lowered shares of Kymera Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, March 7th. Stephens upped their price objective on Kymera Therapeutics from $95.00 to $100.00 and gave the stock an “overweight” rating in a research report on Monday, March 2nd. Royal Bank Of Canada reaffirmed an “outperform” rating and set a $108.00 price objective on shares of Kymera Therapeutics in a research report on Thursday, February 26th. Citigroup upped their price objective on Kymera Therapeutics from $110.00 to $120.00 and gave the stock a “buy” rating in a research report on Monday, March 2nd. Finally, Jefferies Financial Group assumed coverage on Kymera Therapeutics in a research report on Monday, March 16th. They set a “buy” rating and a $110.00 price objective on the stock.

Kymera Therapeutics Stock Performance

Kymera Therapeutics stock opened at $88.77 on Friday. Kymera Therapeutics has a fifty-two week low of $28.06 and a fifty-two week high of $103.00. The firm has a 50 day moving average price of $84.52 and a 200 day moving average price of $75.22. The company has a market capitalization of $7.25 billion, a PE ratio of -24.12 and a beta of 2.28.

Kymera Therapeutics (NASDAQ:KYMR) last posted its earnings results on Thursday, February 26th. The company reported ($0.97) earnings per share for the quarter, missing the consensus estimate of ($0.77) by ($0.20). Kymera Therapeutics had a negative net margin of 794.04% and a negative return on equity of 28.71%. The company had revenue of $2.87 million during the quarter, compared to analyst estimates of $14.80 million. During the same quarter last year, the business posted ($0.88) EPS. The firm’s revenue for the quarter was down 60.8% on a year-over-year basis. As a group, equities research analysts forecast that Kymera Therapeutics will post -3.65 earnings per share for the current year.

Insider Buying and Selling

In related news, insider Noah Goodman sold 1,347 shares of the firm’s stock in a transaction that occurred on Tuesday, April 14th. The shares were sold at an average price of $90.00, for a total value of $121,230.00. Following the sale, the insider owned 50,195 shares of the company’s stock, valued at $4,517,550. This trade represents a 2.61% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, COO Jeremy G. Chadwick sold 1,300 shares of the firm’s stock in a transaction that occurred on Wednesday, April 15th. The shares were sold at an average price of $90.00, for a total transaction of $117,000.00. Following the completion of the sale, the chief operating officer directly owned 61,202 shares in the company, valued at approximately $5,508,180. This trade represents a 2.08% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 344,434 shares of company stock worth $29,191,730 over the last ninety days. Insiders own 16.01% of the company’s stock.

Hedge Funds Weigh In On Kymera Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the company. Smartleaf Asset Management LLC grew its stake in shares of Kymera Therapeutics by 382.0% during the fourth quarter. Smartleaf Asset Management LLC now owns 535 shares of the company’s stock worth $42,000 after purchasing an additional 424 shares in the last quarter. Larson Financial Group LLC grew its stake in shares of Kymera Therapeutics by 81.5% during the third quarter. Larson Financial Group LLC now owns 777 shares of the company’s stock worth $44,000 after purchasing an additional 349 shares in the last quarter. Caitong International Asset Management Co. Ltd acquired a new position in shares of Kymera Therapeutics during the fourth quarter worth $63,000. Bessemer Group Inc. grew its stake in shares of Kymera Therapeutics by 652.0% during the third quarter. Bessemer Group Inc. now owns 940 shares of the company’s stock worth $53,000 after purchasing an additional 815 shares in the last quarter. Finally, Osaic Holdings Inc. grew its stake in shares of Kymera Therapeutics by 18,050.0% during the second quarter. Osaic Holdings Inc. now owns 1,089 shares of the company’s stock worth $48,000 after purchasing an additional 1,083 shares in the last quarter.

About Kymera Therapeutics

Kymera Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in Watertown, Massachusetts, focused on the discovery, development and commercialization of small‐molecule therapies that harness the body’s natural protein homeostasis pathways. Since its founding in 2016, Kymera has pursued a targeted protein degradation platform designed to identify and selectively eliminate disease‐causing proteins. The company’s proprietary Pegasus™ platform integrates insights from ubiquitin biology and medicinal chemistry to advance novel degrader candidates across a range of therapeutic areas.

The company’s pipeline emphasizes immunology and oncology.